251 related articles for article (PubMed ID: 24926508)
1. Lorcaserin. In obesity: unacceptable risks.
Prescrire Int; 2014 May; 23(149):117-20. PubMed ID: 24926508
[TBL] [Abstract][Full Text] [Related]
2. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial.
Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM;
J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446
[TBL] [Abstract][Full Text] [Related]
3. Lorcaserin: an investigational serotonin 2C agonist for weight loss.
Hurren KM; Berlie HD
Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982
[TBL] [Abstract][Full Text] [Related]
4. Safety and tolerability review of lorcaserin in clinical trials.
Greenway FL; Shanahan W; Fain R; Ma T; Rubino D
Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785
[TBL] [Abstract][Full Text] [Related]
5. The safety and efficacy of lorcaserin in the management of obesity.
Hess R; Cross LB
Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762
[TBL] [Abstract][Full Text] [Related]
6. Lorcaserin: drug profile and illustrative model of the regulatory challenges of weight-loss drug development.
Bays HE
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):265-77. PubMed ID: 21438803
[TBL] [Abstract][Full Text] [Related]
7. Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
Bohula EA; Wiviott SD; McGuire DK; Inzucchi SE; Kuder J; Im K; Fanola CL; Qamar A; Brown C; Budaj A; Garcia-Castillo A; Gupta M; Leiter LA; Weissman NJ; White HD; Patel T; Francis B; Miao W; Perdomo C; Dhadda S; Bonaca MP; Ruff CT; Keech AC; Smith SR; Sabatine MS; Scirica BM;
N Engl J Med; 2018 Sep; 379(12):1107-1117. PubMed ID: 30145941
[TBL] [Abstract][Full Text] [Related]
8. Multicenter, placebo-controlled trial of lorcaserin for weight management.
Smith SR; Weissman NJ; Anderson CM; Sanchez M; Chuang E; Stubbe S; Bays H; Shanahan WR;
N Engl J Med; 2010 Jul; 363(3):245-56. PubMed ID: 20647200
[TBL] [Abstract][Full Text] [Related]
9. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial.
Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS
Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985
[TBL] [Abstract][Full Text] [Related]
10. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM
Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689
[TBL] [Abstract][Full Text] [Related]
11. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis.
Nguyen CT; Zhou S; Shanahan W; Fain R
Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567
[TBL] [Abstract][Full Text] [Related]
12. The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?
Woloshin S; Schwartz LM
JAMA Intern Med; 2014 Apr; 174(4):615-9. PubMed ID: 24515599
[TBL] [Abstract][Full Text] [Related]
13. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity.
Nigro SC; Luon D; Baker WL
Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs.
Chan EW; He Y; Chui CS; Wong AY; Lau WC; Wong IC
Obes Rev; 2013 May; 14(5):383-92. PubMed ID: 23331711
[TBL] [Abstract][Full Text] [Related]
15. Lorcaserin Hcl for the treatment of obesity.
Shukla AP; Kumar RB; Aronne LJ
Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579
[TBL] [Abstract][Full Text] [Related]
16. Formulary management of 2 new agents: lorcaserin and phentermine/topiramate for weight loss.
Kelly EM; Tungol AA; Wesolowicz LA
J Manag Care Pharm; 2013 Oct; 19(8):642-54. PubMed ID: 24074010
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials.
Singh AK; Singh R
Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials.
Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S
Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931
[TBL] [Abstract][Full Text] [Related]
19. New obesity agents: lorcaserin and phentermine/topiramate.
Fleming JW; McClendon KS; Riche DM
Ann Pharmacother; 2013; 47(7-8):1007-16. PubMed ID: 23800750
[TBL] [Abstract][Full Text] [Related]
20. Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss.
Prescrire Int; 2015 Oct; 24(164):229-33. PubMed ID: 26594724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
